Who to call at Sarepta Therapeutics, Inc., and when
Fundz watches for the moments Sarepta Therapeutics, Inc. starts buying, and tells you who to reach.
- An alert the day Sarepta Therapeutics, Inc. raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at Sarepta Therapeutics, Inc., from your own LinkedIn network
Sarepta Therapeutics, Inc.
The company signed a major contract or deal. An 8-K is the notice a US public company must file within four business days of a major event.
www.sarepta.comAI Executive Summary
AI-powered analysis of 8-K filing content
Sarepta Therapeutics settled patent infringement litigations with REGENXBIO, UPenn, and Catalent on September 23, 2026, resolving disputes over two U.S. patents with a $39 million charge, reducing legal uncertainty and allowing the company to move forward operationally.
Key Takeaways
Settlement resolves pending patent infringement litigations and appeals involving U.S. Patent Nos. 11,680,274 and 10,526,617
Sarepta recorded a $39.0 million litigation contingency charge to cover the settlement obligations
2 more takeaways
Filing Overview
What This Means
Sarepta Therapeutics, Inc. filed with the SEC. Fundz turns 8-K material events into an alert with the right executive attached.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
4 screens from a live account. No signup.